Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Completed · Phase 2

Conditions studied: Intracerebral Hemorrhage

In brief

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Key facts

Study ID

NCT00961532

Run by

Northwestern University

People needed

14

Starts

2010-12-01

Expected to finish

2013-12-01

Last updated by the study team

2014-08-28

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Spontaneous intracerebral hemorrhage as documented by head CT scan
• Documented regular aspirin use or VerifyNow-ASA result of ≤ 550 aspirin reaction units (ARU), indicating anti-platelet medication

You may not qualify if…

• International normalized ratio (INR) of ≥ 1.7 from coagulopathy or warfarin use
• History of von Willebrand disease
• Pregnancy
• Known hypersensitivity to DDAVP or desmopressin
• Active cardiovascular disease or unstable angina
• Hyponatremia or history of hyponatremia
• Current or historical deep venous thrombosis or pulmonary embolism

Where it is running

• Northwestern Memorial Hospital — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.